Sentences with phrase «cell treatments involving»

Not exact matches

In clinical trials the treatment — which involves extracting individual patients» immune T - cells, modifying them to seek out tell - tale biological markers associated with blood cancers like aggressive lymphoma, and then pumping those modified killer cells back into the body — has shown major promise, in some cases eliminating all signs of the cancer in patients six months after treatment.

Those two companies, along with their larger competitor Novartis (nvs), are developing experimental chimeric antigen receptor T - cell (CAR - T) technology platforms, which are highly personalized treatments that involve extracting patients» immune cells, re-engineering them to target their specific cancers, and then pumping these sniper - cells back into the body.

The novel treatment space involves transforming a patient's own immune T - cells into cancer - busting weapons.

Bellicum is among the flurry of biotechs investing heavily into cell therapies such as experimental chimeric antigen receptor T - cell (CAR - T) treatments for cancer (this is the next - gen treatment that involves reprogramming immune cells to become cancer killers and has shown promise in blood cancers, which Bellicum specializes in).

It's the second approval for this pioneering approach to cancer treatment, which involves re-engineering patients» own immune cells to become cancer killers, after the FDA's approval of Novartis» Kymriah in August.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Treatment typically involves chemotherapy (using chemicals intravenously to kill cancer cells), radiation therapy (using high - powered X-rays to kill cancer cells), or surgery to remove the breast and surrounding lymph nodes.

Although the researchers emphasized that laboratory results involving cell lines and mice do not necessarily translate to human treatment, they say their findings show that new mTOR inhibitors combined with chemotherapy could become a new treatment strategy for T - ALL.

A «Trojan horse» treatment for an aggressive form of brain cancer, which involves using tiny nanoparticles of gold to kill tumour cells, has been successfully tested by scientists.

But the viral method involves inserting the DNA for the protein into cells instead, which means the cutting protein keeps being made for weeks after treatment.

The study involved 23 patients with relapsed or treatment - resistant HL, a cancer of white blood cells called lymphocytes.

«The iPS cells may also help us identify treatments for more common diseases, such as atherosclerosis and vascular calcification, because the same bone morphogenetic protein pathways are involved in these medical conditions.»

Those hoping for quick clinical success should remember it takes time for revolutionary treatments to go from lab bench to bedside, says Andras Nagy, a stem cell researcher at Mount Sinai Hospital's Lunenfeld — Tanenbaum Research Institute in Toronto, who has not been directly involved in Yamanaka's work.

Because AML is difficult to treat, standard treatment commonly involves multiple chemotherapy medicines that are given at a higher dose in order to kill the cancer cells.

One potential treatment involves injecting the wound with stem cells, which can change into other cell types, such as skin cells like keratinocytes, to help with the healing process.

In all instances, treatments involving the antibody — whether alone or in combination with chemotherapy — appeared to eradicate more cancer cells compared to standard care.

As part of the long effort to improve treatment of tuberculosis (TB), microbiologists led by Yasu Morita at the University of Massachusetts Amherst report that they have for the first time characterized a protein involved in making a glycolipid compound found in the TB cell wall, which is critical for the disease - causing Mycobacterium to become infectious.

The treatment involves collected blood stem cells carrying the genetic anomaly of patients and corrected them in the laboratory by introducing a healthy WAS gene using a lentiviral vector developed and produced by Genethon.

Scientists who discovered a cell «machine» involved in protein folding and a life - saving treatment for malaria are this year's recipients

«RNAi therapies are a unique approach to cancer treatment as they have the potential to «turn off» the genes» coding for proteins involved in cancer cell division,» said Ramesh K. Ramanathan, M.D., medical director of the Virginia G. Piper Cancer Center Clinical Trials Program at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of the Translational Genomics Research Institute (TGen) in Phoenix, Ariz. «Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth.»

, the researchers described the case of a man with an acute lung disorder, in which he received an experimental treatment involving the use of his own blood - derived cells and the drug erythropoietin, which stimulates the production of red blood cells.

Treatments in Germany involving adult stem cells will be more closely regulated after revision of Germany's medical products law received final approval by the Bundesrat, the upper house of parliament.

Although cord blood stem cell transplant is becoming increasingly promising, the Clinical Islet Program is not currently involved with cord blood as a treatment for diabetes.

The focus of diabetes treatments and research involves targeting immune responses and beta cell regeneration.

The Bundesrat approved the revisions on 10 July, just over two weeks after the German Society for Neurology and the German Parkinson Society issued a joint statement warning that patients with Parkinson's disease should not undergo treatments involving bone marrow stem cells.

Their compound, which is intended to repair brain damage that has already occurred, is a significant departure from current Alzheimer's treatments, which either slow the process of cell death or inhibit cholinesterase, an enzyme believed to break down a key neurotransmitter involved in learning and memory development.

New study have identified the inhibitor of a protein involved in cell protection as a potential target for novel Alzheimer's treatment

A noted expert in his field, Dr. Collins has since the late 1980s helped to develop the treatment known as adoptive immunotherapy, which involves manipulating a donor's immune system so that it attacks cancer cells.

Platelets (or thrombocytes) control the process of blood clotting and transfusions are common to prevent bleeding in treatments involving hematopoietic stem cell (HSC) and bone marrow (BM) transplantation [1].

In some countries, this phenomenon traditionally has been called stem cell tourism because it involved travel to another country with less stringent regulations to obtain treatment.

Clinical trials involving CAR - T cells have offered cancer patients who have exhausted traditional chemotherapy treatment options a new lease on life.

This involved a bone marrow transplant, which he underwent as part of treatment for leukaemia, using a donor with a rare genetic mutation rendering their cells resistant to HIV.

Treatment strategies involving neurotrophic factors are now based on the transfer of genes, molecules or cells into the nervous system [122].

This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.

Also, genes that code for receptor tyrosine kinases, a family of receptors on the surface of cells, may rearrange to form multiple distinct gene fusion partners, as evidenced in an article by Kulkarni, et al, on a translational study involving a patient who developed a BRAF fusion following treatment with a BRAF inhibitor1.

The Treatment: Autologous hematopoietic stem cell transplantation (AHSCT) is an aggressive procedure which involves collecting stem cells from an...

The challenge takes on even more urgency with recent developments, including a federal administration now more open to exploring the potential of stem cells, the recent FDA approval of a human trial involving embryonic stem cells, as well as the reported case of a young boy who developed a brain tumor four years after receiving a stem - cell treatment for a rare genetic disorder.

Meanwhile, a clinical trial similar to PreSERVE - AMI involving treatment with mesenchymal bone marrow cells is currently underway at Emory, sponsored by CardioCell / Stemedica.

The stem cell approach I am most excited about involves a treatment to replace cells called retinal pigment epithelial cells.

As we have previously suggested, since tumor angiogenesis is very complex and involves a number of different cell types, a multi-target approach for the anti-angiogenic treatment of cancer could be expected to produce better results [18].

Radiation therapy (also referred to as radiation oncology) is a type of cancer treatment that involves the use of the use of high - energy radiation, primarily X-rays, to kill cancer cells and shrink tumors.

One of our goals is to understand more precisely the mechanisms involved in the response to treatments designed for leukemia and lymphoma, two cancers linked to overproduction of blood cells.

He also developed the first treatment protocol for MS involving the transplantation of stem cells in the U.S. Along with his peers, Dr. Kraft identified the importance of treating the secondary effects of MS, known as hidden disabilities, including cognitive impairments, pain, fatigue, sleep disturbance, and depression.

Although treatment steps may vary slightly from patient to patient depending on what condition is being treated, each stem cell procedure involves three basic steps:

In recent years, immunotherapies, such as those involving chimeric antigen receptor (CAR) T cells, have become increasingly promising approaches to non-small-cell lung cancer (NSCLC) treatment.

Acute myeloid leukemia (AML) is the leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete remissions with front - line therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.

1) Phytonutrients: * Occur naturally in fruits and vegetables * Promote the function of the immune system * Help fight off viruses as well as reduce inflammation * Associated with the treatment and / or prevention of cancer and cardiovascular disease 2) Enzymes: * Responsible for metabolic processes that occur within a cell and are necessary for sustaining life * Assist and play a large role in digestion, energy production, blood coagulation and contraction of muscles 3) Amino Acids: * The basic building blocks of protein * Absorption of amino acids is essential for your metabolism 4) Essential Fatty Acids: * Reduce the risk of heart disease and some forms of cancer * Improve mood * Decrease inflammation 5) Vitamins: * Essential for the normal growth and development of all human beings * Healthy maintenance of cell tissues and organs * Help process proteins, carbohydrates and fats required for utilization 6 & 7) Macro and Trace Minerals: * Involved in electrolyte balance of body fluids * Essential for normal cellular activity * Provide hardness to bones and teeth

Also, a promising type of treatment involves niacin flushing coupled with gentle exercise and sauna to get these pollutants out of the fat cells and out of the skin.

Because of this, it has been used as a treatment in issues that involve cell division like in the treatment of infertility in men as cell division is necessary for sperm production.

This treatment — considered experimental and investigative in the United States — involves harvesting stem cells from fat obtained in a mini-liposuction procedure, and reinjecting their own stem cells.